Moderna's RSV vaccine shown to provide strong protection against serious cases in adults 50 and older
A single dose of Moderna's mResvia RSV vaccine was 60.3% protective against documented respiratory syncytial virus (RSV) infections, 60.2% against RSV-associated emergency department or urgent care encounters and 81.8% against RSV-associated hospitalizations in a population of older U.S. veterans, according to a recent study in JAMA Network Open.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
